Pharma BD Deal Intelligence
Pfizer acquired Anacor Pharmaceuticals for $5.2B for inflammation and immunology drugs.
Credit Suisse analyst Vamil Divan: the deal fits Pfizer's strategy of acquiring late-stage or approved drugs and leaves ample firepower for additional M&A;…
Pfizer's $99.25/share offer represented a ~55% premium and was framed as a bid to rebuild the inflammation/immunology pipeline after the failed Allergan…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Pfizer acquired Anacor Pharmaceuticals for $5.2B for inflammation and immunology drugs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Anacor Pharmaceuticals (this deal) | 2016 | $5.2B | 43 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2016 deals · Pfizer Inc. deals · Dermatology deals